To overcome the many challenges posed by the use of viral vectors (High development and manufacturing costs, production scale up complexity, immunogenicity and genotoxicity risks...), we are developing a unique DNA vector to reduce the cost and improve efficiency of gene therapy. Indeed, Fabmid develops a DNA vector both easy to produce and with all the properties required from a good vector: high cell transfection efficiency, low toxicity, high stability and selectivity.
| Website | https://www.fabmid.com |
| Employees | 2 (2 on RocketReach) |
| Founded | 2020 |
| Industry | Biotechnology |
| Keywords | Gene Therapy, Recombinant Dna, Vector Production, Genetic Engineering, Dna Technology, Drug Development, Genetic Medicine, Cell Therapy, Pharmaceutical Manufacturing, Bioprocessing, Pharmaceutical Production, Biologics Manufacturing, Biotechnology, Molecular Biology, Drug Delivery, Therapeutics, Clinical Trials, Life Sciences |
Looking for a particular Fabmid employee's phone or email?
Clément Josset is the Co-founder of Fabmid.
2 people are employed at Fabmid.